Cytokine testing for COVID-19 risk stratification and treatment monitoring
Cytokine testing for COVID-19 risk stratification and treatment monitoring
11 June 2020
Cytokine testing for COVID-19 risk stratification and treatment monitoring
On Biomedical Science Day 2020, an innovative method of monitoring treatment efficacy and recovery of COVID-19 has been unveiled by global diagnostics company Randox Laboratories.
The test, which looks for the presence of cytokines (a type of small protein) is performed on Randox’s patented Biochip Technology, which can simultaneously detect multiple analytes from a single patient sample.
Cytokines play a vital role in the immune system and are known to be involved in the body’s response to a variety of inflammatory and infectious disease, such as COVID-19.
Lynsey Adams, Randox Marketing Manager, commented;
“Cytokine storms, which are the overstimulation of cytokines in response to infection, are a common complication of severe cases of COVID-19, and can trigger excessive, uncontrolled systemic inflammation.
“The monitoring of cytokine proteins therefore offers a unique opportunity to identify patients who, as a result of this viral sepsis, are at risk of poor disease outcomes including pneumonitis, Acute Respiratory Distress Syndrome, respiratory failure, shock, or even organ failure.
“Treatment for any infection, COVID-19 included, is most effective when administered at an early stage, and so the detection of cytokine storms within COVID-19 patients could provide vitally important information that will direct the appropriate patient care pathway and facilitate improved patient outcomes.”
The comprehensive cytokine testing menu from Randox comprises of 26 different cytokines, across four different biochip panels.
Designed to make cost, time and resource savings for a range of diagnostic laboratories, Randox Cytokine Biochips can detect up to 12 cytokines and growth factors from a single patient sample.
Lynsey continued;
“The multiplex capabilities of the Randox Biochip will provide clinicians with a more comprehensive picture of the patient’s condition.
“Compatible with our Evidence and Evidence Investigator analysers, which are capable of processing 2960 and 2376 tests per hour respectively, Randox Cytokine Biochip panels offer a comprehensive testing method for these proteins which play such a central role in the immune system.”
In addition to COVID-19 risk stratification, cytokine testing has also been linked to monitoring for allergies, vascular diseases, cancer, and a range of autoimmune diseases.
Key Benefits of Randox Cytokine Testing
- Simultaneous detection of up to 12 cytokines and growth factors from a single patient sample
- Fully automated and semi-automated testing platforms available to suit all laboratory throughputs
- Comprehensive test menu comprising 26 cytokines, cytokine receptors and growth factors
- Suitable for use with serum and plasma samples
- Excellent analytical performance
- Availability of complementary quality controls for a complete testing package
For more info please visit www.randox.com/cytokine-testing-solutions/, email marketing@randox.com or phone 028 9442 2413
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our Randox Products and Services
REAGENTS
RX SERIES
ACUSERA
BIOCHIP
We Are Randox | How Ciara Taylor became R&D Team Leader at Randox
We Are Randox | How Ciara Taylor became Clinical Immunoassay R&D Team Leader at Randox
In support of our new £30m COVID-19 laboratories, we are hiring 200 new staff across Engineering, Manufacturing and Science.
For an idea of what it’s like to be a scientist at Randox, we spoke to R&D Team Leader Ciara Taylor.
Ciara spoke to us about the route she took to her current role, what advice she would give someone following a similar career path, and what makes her job so important.
Name: Ciara Taylor
Job Title: R&D Team Leader
Department: Clinical Immunoassay R&D
Ciara, can you give us a quick summary of what your job entails?
Our team works on the research and development of new clinical diagnostic tests for a variety of common health conditions, such as heart disease. We carefully design and execute laboratory experiments to ensure our tests perform at an exceptionally high level for hospitals and laboratories around the world.
What did you study and where?
I studied a four-year integrated Chemical Engineering Masters degree at Queen’s University Belfast. It was an ideal choice for me as it encompassed areas of the subjects I had enjoyed at school; Chemistry, Physics, Biology and Maths. I gained a lot of experience in research during my final year industrial project.
Give a brief outline of your career to date
I finished my university degree in 2016. I worked for an Engineering consultancy firm for 6 months, and then spent some time travelling before joining Randox in October 2017. In my first year I spent time learning about the science behind immunoassay development and how to apply to our research work. At the end of 2018, I was promoted to Research and Development (R&D) Team Leader, giving me more responsibility over the training of staff, and the progress of new projects, from initial concept and feasibility to product validation. I have also had the opportunity to travel and represent the company in conferences, events and career days.
Is this what you always wanted to do?
When I was younger I honestly had no idea what my ideal job would be. I simply knew that I wanted a dynamic role that involved working with people on challenging and interesting projects, which is exactly what I have here at Randox. I love the variety and opportunity that a global company like Randox offers as we are always trying to evolve and keep up with the latest industry demand. Currently every department is working together to process large-scale testing for COVID-19, as part of the government’s national testing programme.
Were there any particular essential qualifications or experience needed?
We have people of varying degree backgrounds in our team including Chemistry, Chemical Engineering, Biochemistry, Biomedical, Biological or Pharmaceutical Sciences. Experience in a similar R&D capacity is also helpful, though we offer full training to those who may have little experience specifically in diagnostics, but who possess a general science background.
Are there alternative routes into the job?
Whilst I joined Randox as a graduate R&D scientist following university, there are other routes available. Some of my colleagues began their careers by doing a placement year with Randox or by taking part in our Graduate Programme, in which graduates rotate across different areas of the business to find a job best suited to their skills and interests. Also available as an option is the Randox APEX scheme, which gives first year university students a summer and a third-year placement, and a job offer upon graduating. Naturally we also have a lot of PhD graduates join R&D, as they are ideal candidates for conducting research. Another route, if you don’t have the A-Levels for a university degree, is to go to a Technical College and gain an equivalent qualification in a science discipline. This could lead to a placement opportunity and later job with Randox.
What are the best and most challenging aspects of the job?
The best part of working in Randox is the people you work with. We work very collaboratively across different departments, and our staff come from a wide variety of backgrounds, so I am constantly learning from everyone around me and bouncing ideas off different people with different skillsets.
The most challenging aspect is the same in every R&D role – sometimes the initial feasibility experiments just don’t give the results you had expected. The rewarding part lies in solving the problem and making a breakthrough in your research project.
Why is what you do important?
The development of clinical diagnostic tests has a direct impact on the quality of healthcare that people receive around the world. It is rewarding to be part of a global company that is trying to improve people’s lives by providing a more personalised diagnosis using the tests we develop. As a company, Randox is continually investing money into the research of novel clinical biomarkers and testing platforms, showing its commitment to the improvement of diagnostics and ultimately, patient outcomes.
What advice would you give anyone looking to follow a similar career path?
If you are interested in R&D, keep your options and searches open. I didn’t know how much I would enjoy clinical R&D until I started at Randox. It makes a difference when you are genuinely interested and take pleasure in the work you do. Previous lab experience is ideal, so I would recommend trying to do a placement or getting some relevant work experience, especially if your degree doesn’t include much practical lab work.
If you weren’t working in Clinical Immunoassay R&D what would you like to do?
I would still love to be in a research role, perhaps in renewable or clean energy sources.
Describe your ideal day off
My ideal day off involves exercise or eating! I would go for a swim, yoga or a long walk, and then go out for dinner. I love trying new restaurants.
We are delighted to have Ciara with us at Randox as part of our incredibly talented R&D team.
For current vacancies at Randox please visit careers.randox.com
For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.
For further information please email recruitment@randox.com or phone 028 9442 2413.
Want to know more?
Contact us or visit our Randox Careers
Find out more about Randox Careers
Careers News
Vacancies
Our People
Careers Website
CE marking granted to Quality Control for newborn infectious disease tests
08 June 2020
CE marking granted to Quality Control for newborn infectious disease tests
ToRCH Quality Controls to support the accuracy and reliability of infectious disease testing in newborns, have been granted CE marking.
The controls for ToRCH, which is a blood test screening to detect infectious diseases including toxoplasmosis, rubella, cytomegalovirus, and herpes simplex, are available from global diagnostics company Randox Laboratories, and are used to ensure accurate ToRCH test and system performance.
Manufactured from human plasma, each control is designed to react to the test system in the same manner as the patient sample, helping laboratories to meet ISO 15189:2012 for quality and competence.
Lynsey Adams, Randox Quality Control Manager, commented;
“The CE marking of the ToRCH controls from Randox will be a game-changer for clinicians and patients alike, by facilitating early, accurate and comprehensive diagnoses of infectious diseases in newborns, that allow for the best possible patient outcomes.
“Ultimately, these ToRCH controls will guarantee quality assurance in laboratories performing ToRCH screening in newborns.”
Randox ToRCH Controls are also multi-analyte and therefore, testing can be consolidated to just a small number of vials to save laboratories valuable space and time.
In addition to ToRCH, Randox Infectious Disease Quality Controls also include quality control material for Lyme Disease, Epstein-Barr virus, HIV, Hepatitis A virus, Human T-lymphotropic virus, Cytomegalovirus, and Varicella zoster virus (Chickenpox or Shingles).
Lynsey continued;
“Unlike analyser-specific tests, these controls can be used across a wide range of laboratory technologies, and complement our already existing RIQAS Serology EQA programmes to provide laboratories with a complete QC solution from a single supplier.
“With a working stability of 60 days at 2°c to 8°c which keeps waste and costs to a minimum, Randox Infectious Disease Controls are set to revolutionise serology testing and provide reliable, accurate results time and time again.”
Randox Infectious Disease Controls are ideal for microbiology and virology laboratories, blood banks, public health laboratories or clinical laboratories performing serology testing.
Key benefits of the Randox Infectious Disease Controls;
- User-friendly – all samples are provided in a liquid, ready-to-use format
- Commutable – manufactured from human plasma, each control reacts to the test system in the same manner as a patient sample
- Versatility – designed to deliver an independent, unbiased assessment of performance with any immunoassay instrument
- Stability – working stability of 60 days ensures waste and costs are kept to a minimum
- Multi-marker – helps reduce the number of individual controls required
- Clinical relevance – designed to challenge clinically-relevant levels, samples will ensure accurate and reliable instrument performance
For more information visit https://www.randox.com/torch-controls/
QUALITY CONTROL
REAGENTS
RX SERIES
We Are Randox | How James Davidson became a Mechanical Design Engineer at Randox
We Are Randox | How James Davidson became a Mechanical Design Engineer at Randox
At the beginning of April we announced we are recruiting mechanical, electrical and manufacturing engineers to enhance our capacity for COVID-19 testing. The engineers will be involved in the fast-tracked development of specialist molecular analysers used to detect the presence of COVID-19.
For an idea of what it’s like to work in engineering at Randox, we spoke to Mechanical Design Engineer James Davidson.
James spoke to us about the route he took to his current role, the best and most challenging things about his job, and how he likes to spend his well-deserved time off.
Name: James Davidson
Job Title: Mechanical Design Engineer and Project Coordinator
Department: Engineering
James, can you give us a quick summary of what your job entails?
My main responsibilities are designing new medical testing analysers, updating and developing our existing machines and conducting troubleshooting to make sure that they are performing correctly. I also train new and existing staff on Randox technologies.
What was your favourite subject at school?
I really enjoyed Maths at school, for the challenge of being able to solve a logical problem and get to the correct conclusion by the end of your working out.
What was the route you took into your job?
My A-levels didn’t go to plan at school and I found myself in a difficult situation where I didn’t have the grades to go to university as I had planned.
I subsequently went along to an information evening at the Northern Regional College in Ballymena where I found out about the Higher National Diploma in Manufacturing Engineering, which really appealed to me and suited my interests. I knew straight away that it’s what I wanted to do so I started the course a week after that and really enjoyed it. Completion of the HND opened the door to enroll in a degree in Mechanical Engineering at the University of Ulster in Jordanstown, where I graduated with a 2:1 in 2012. I secured a placement at Randox in 2010 as part of this degree course which ultimately led me to the role that I am currently in.
Give a brief outline of your career to date
The year-long placement I did at Randox taught me a lot. I enjoyed it so much that I came back to Randox after my degree and have been here since! Throughout my time in Randox I have worked on different projects that have each been at different design stages – from concept right through to market release. I was promoted to Project Coordinator in 2016 and placed in charge of a small team of mechanical engineers. In this role I plan new work for each member of the team, review designs and provide assistance if required. I love being part of the Engineering team at Randox. It’s a really creative environment and we all work collaboratively together – bouncing ideas off each other and supporting each other when needed.
Is this what you always wanted to do?
I have always had an interest in how things work so a career in engineering was a natural progression for me. The world is constantly changing with new innovations and solutions to better people’s lives and I’m happy to be involved in an area of engineering that is bettering such a key part of people’s lives – their health.
Are there alternative routes into the job?
There are several potential routes to becoming a mechanical design engineer. Whilst I didn’t take the traditional route to become a design engineer – completing A-levels and then going to university – this would be the most common option. Alternatively, you can do what I did and study an HND before then getting a degree. Experienced engineers with a Higher National Certificate/Diploma could also be considered for the role.
What are the main personal skills your job requires?
For a mechanical design engineer the main essential skills would be an ability to work as part of a team, the ability to problem solve, knowledge of manufacturing processes and a flair for design. The ability to work under pressure and a high attention to detail are useful skills to have as well.
What does a typical day look like for you?
It might sound cliché, but every day is different! Up until earlier this year I was part of a product development team who design machines for a range of clinical conditions. More recently I have been involved in the design and development of a specialist COVID-19 testing system that will dramatically increase our capacity to process samples.
What are the best and most challenging aspects of the job?
It is simultaneously gratifying and challenging to experience the full cycle of project development from start through to finish. It requires quite a lot of patience.
Why is what you do important?
By guaranteeing that diagnostic machines are performing correctly, I am essentially making sure that patients across the globe are getting the correct medical diagnosis and follow-up treatment. These machines are life-saving devices.
If you weren’t a Mechanical Design Engineer what would you like to do?
My dad and brother own a garage so I think I would be working as a mechanic with them. It would harness the same skills and interests as my current role! I have also considered the possibility of being a teacher.
Describe your ideal day off.
I enjoy water skiing so on my days off, if the weather is good, I like to go out on the water. It’s a great way to blow off some steam.
And finally, what’s the key to any successful job search?
My advice to anyone currently looking for a job would be to find something with a lot of variety. You don’t want to be doing the same thing over and over again and you need to keep things interesting. I’m proud to say that my job at Randox has held my interest for the best part of a decade!
We are delighted to have James with us at Randox as part of our incredibly talented engineering team.
For current vacancies at Randox please visit careers.randox.com
For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.
For further information please email recruitment@randox.com or phone 028 9442 2413.
Want to know more?
Contact us or visit our Randox Careers
Find out more about Randox Careers
Careers News
Vacancies
Our People
Careers Website
Randox announces its Ā£30m investment in specialised COVID-19 testing lab
Randox invests £30m and 200 new jobs in specialised COVID-19 testing lab
As part of efforts to enhance its national testing capacity, global diagnostics company Randox has announced an investment of £30m in a new specialised COVID-19 testing hub.
The healthcare firm, which is currently conducting COVID-19 tests as part of the national testing programme, announced its investment in the new facilities based at the Randox Science Park in Antrim, Northern Ireland, during a visit yesterday by the Secretary of State for Northern Ireland, The Rt Hon Brandon Lewis CBE.
The specialised laboratory, the development of which was fast-tracked over the space of four weeks, is the first step in a wider diagnostics investment programme from Randox.
Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;
“The national testing programme, as a collaborative effort by government and various partners within industry, has increased testing capacity at an unparalleled speed – by installing a network of drive-through testing centres, introducing home testing kits, and now, opening this specialised lab at the Randox Science Park in Northern Ireland.
“An incredible amount of work has gone into making this cutting-edge testing facility a reality in a relatively short space of time, as we know that effective testing is the most effective way to both save lives and promote a timely return to a more normal society.”
The opening of the new laboratory at the Randox Science Park follows the company’s announcement that it is recruiting new staff across Science, Engineering and Manufacturing in support of its role within the national testing programme.
The 200 new positions will be involved in the testing of potential COVID-19 samples, as well as the construction of 200 new state-of-the-art diagnostic analysers which will significantly increase Randox’s capacity for COVID-19 testing.
Dr FitzGerald continued;
“Now that we have in place the infrastructure and laboratory space required to enhance our testing capacity, we look forward to implementing the next step in our COVID-19 investment programme.
“By accelerating the build schedule for new specialised equipment, and hiring 200 associated workers across Science, Engineering and Manufacturing we will further enhance the government’s national testing scheme, as well as facilitate testing more broadly across the general populace.”
Secretary of State Brandon Lewis MP welcomed the new investment saying:
“I was impressed during my visit with the dedication of staff and the top-class facilities at Randox. This investment will help support the UK’s nationwide effort to fight the coronavirus and ultimately save lives.”
Dr FitzGerald concluded;
“I would also like to take this opportunity to pay tribute to all my colleagues at Randox who continue to work assiduously to process such a high volume of tests in a timely manner.
“I know I speak on behalf of everyone when I say we appreciate all your hard work and the vital role you play in the practical application of COVID-19 testing.”
For further information please email randoxpr@randox.com
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our Randox Products and Services
REAGENTS
RX SERIES
ACUSERA
BIOCHIP
Norbrook partners with Randox on staff screening programme for COVID-19
Pharmaceuticals company Norbrook Laboratories has revealed that it will be the first company in Northern Ireland to install an innovative COVID-19 testing platform for on-site staff screening.
The Newry-based firm, which specialises in the development of pharmaceuticals for the veterinary industry, will begin testing for its workforce in the coming weeks, to provide reassurance and peace of mind for colleagues and for their families, without impacting on the public health need.
The COVID-19 screening programme at Norbrook is being facilitated by diagnostic technology from global diagnostics company Randox, one of the partners within the national COVID-19 testing programme.
David Ferguson, Managing Director at Randox Food Diagnostics explained;
“Collectively we are all working towards a timely return to a more normal society, which will see companies reopening and people returning to work.
“To facilitate this recovery of the economy, without compromising the health of workers or of the wider general public, workplaces have a responsibility to provide a safe working environment.
“We know that the health of Norbrook’s staff is their priority and as such it is great to see them taking a proactive approach to testing.”
The COVID-19 screening programme at Norbrook is the first in Northern Ireland being facilitated by an innovative testing platform capable of processing results in 2hours 30 mins.
The technology, named the Vivalytic, can screen for SARS-CoV-2, the virus that causes COVID-19, as well as a range of other viral and bacterial infections including Influenza A and B, Pneumonia and other coronaviruses.
David added;
“Randox is fully committed to supporting the national effort to fight COVID-19 by testing at scale, and as we continue to work alongside the government and ramp up our testing capabilities, we welcome the fact that other organisations are also adopting our innovative COVID-19 testing technologies to address their own particular testing needs.
“The Vivalytic, which provides high quality molecular testing for COVID-19, on-site and without the need for laboratory experience, is a unique space-saving, hygienic solution for personnel COVID-19 testing in any setting and will help a wide variety of industries get back to business by ensuring the highest level of safety.”
Denise Collins, Norbrook Human Resources Director, concluded;
“We’re proud to be working with a company like Randox which has such vast experience in the diagnostics industry and was subsequently able to respond so quickly to the COVID-19 pandemic.
“That this world-leading technology is available from a Northern Ireland-headquartered company presents a unique opportunity for workplaces here to quickly and easily implement a staff screening programme, and at the same time demonstrate a high standard of duty of care that should be shown by employers to their employees.”
For further information about the Vivalytic please email marketing@randox.com
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our Randox Products and Services
REAGENTS
RX SERIES
ACUSERA
BIOCHIP
Whole pathogen molecular controls for SARS-CoV-2 (COVID-19) receive CE marking
25 May 2020
Whole pathogen molecular controls for SARS-CoV-2 (COVID-19) receive CE marking
CE marking has been granted to whole pathogen quality controls for SARS-CoV-2 (COVID-19), from global diagnostics company Randox Laboratories.
The molecular controls are currently being used alongside the firm’s pioneering COVID-19 tests, performed on its proprietary Biochip, as part of a nationwide UK testing programme.
Randox is using these third-party quality controls, which include a Positive Control, Negative Control, Analytical Q Panel and Molecular Q Panel, to ensure accurate coronavirus test and system performance, and ultimately, guarantee laboratory quality assurance.
Lynsey Adams, Randox Quality Control Manager, explained;
“Accurate and reliable laboratory testing is an essential aspect of COVID-19 disease management and outbreak control.
“Designed specifically for laboratories currently managing COVID-19 testing, Randox SARS-CoV-2 controls, which have been CE marked, help ensure the accuracy and reliability of molecular assays used in the testing of suspected coronavirus samples, and importantly, give clinicians absolute confidence in any COVID-19 diagnoses they may make.”
Available under the brand name Qnostics, the new SARS-CoV-2 controls are manufactured using whole pathogens. They therefore mimic the patient sample, providing the best sample matrix for laboratories.
Lynsey continued;
“The Randox Qnostics SARS-CoV-2 controls are clinically relevant for full-process validation. Liquid frozen for user convenience and ease of use, the development of the controls using whole pathogen material ensures clinical relevance from extraction to amplification and detection.”
The new coronavirus controls from Randox, which contain the entire SARS-CoV-2 genome, including the conserved regions recommended by CDC and WHO, are compatible for use with both commercial and in-house testing methods, and are quantified by digital PCR to ensure batch to batch reproducibility.
Lynsey added;
“We are proud to be able to support the high demand for coronavirus testing by delivering a full COVID-19 testing package – not only our Coronavirus Biochips but now also the corresponding molecular control material that will ensure the delivery of accurate, and reliable results.
“The World Health Organization (WHO) has been very clear about the importance of testing in the global efforts to contain and delay COVID-19 and we are pleased that our new CE-marked controls comply with guidelines not only from the WHO but also from the Centres for Disease Control and Prevention.”
Randox Qnostics SARS-CoV-2 Controls are heat-inactivated to be non-infectious and are manufactured to ISO 13485 standards.
Key Features and Benefits of Randox SARS-CoV-2 Qnostics Controls:
- Whole pathogen – the controls contain the entire SARS-CoV-2 genome meaning they are compatible with the majority of commercial and in-house assays, and target the CDC and WHO consensus sequences
- Monitor the entire testing process – whole pathogen controls are the ideal clinically relevant material for full-process validation, from extraction to amplification and detection, to ensure ultimate quality assurance in laboratories.
- Non-infectious – the controls are heat-inactivated and gamma-irradiation enabling safe handling of material.
- Highly characterised – the controls are quantified by digital PCR to ensure batch to batch reproducibility.
- Clinically relevant – performance data is available to support the clinical relevance and the compatibility with molecular assays currently in use in clinical laboratories.
- High Quality – the controls are manufactured under ISO 13485 guidelines and are therefore suitable for a broad range of usage.
- Liquid for Ease-of-Use – conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.
- Complete QC package – Analytical and Molecular Q Panels available for new assay validation as well as routine performance monitoring.
For more information visit www.randox.com/coronavirus-randox
QNOSTICS
QCMD
CORONAVIRUS
Randox calls upon NI engineers to build COVID-19 testing platforms
RANDOX CALLS UPON NI ENGINEERS TO BUILD COVID-19 TESTING PLATFORMS
Randox Laboratories has today announced it is recruiting 160 mechanical, electrical and manufacturing engineers to enhance its capacity for COVID-19 testing.
The engineers, who are due to begin work at the Randox Science Park from the middle of May, will be involved in the fast-tracked development of specialist molecular analysers used to detect the presence of COVID-19.
These testing platforms will be used to further enhance the government’s national testing scheme for key workers, as well as to facilitate testing more broadly across the general populace.
Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;
“It is Randox’s priority to ensure that we support the UK’s effort to fight COVID-19, by testing at scale. We know that this is the most effective way to both save lives and promote a timely return to a more normal society.
“We continue to ramp up our COVID-19 testing capabilities – not only by increasing our production of testing kits, but also by accelerating the build schedule for the testing analysers on which the tests are performed.
“We are aiming, by working at maximum efficiency in a greatly accelerated time frame of 6-7 weeks, to manufacture 200 of our most state-of-the-art testing platforms, which will greatly enhance our testing capacity at Randox.”
Randox has, in recent weeks, established a number of new teams responsible for the development, manufacturing and distribution of COVID-19 testing kits for the national testing programme.
The company is also interested in speaking to anyone with experience in mechanical, electrical or manufacturing engineering. Invest Northern Ireland is helping by contacting companies which may be able to temporarily release resources to help meet this urgent staffing requirement.
Dr FitzGerald added;
“To meet the unprecedented demand for COVID-19 testing, we have been redeploying our own personnel to various COVID-19 critical departments, but are now also recruiting for a number of specialist disciplines.
“Everyone at Randox has a vital role to play in the practical application of COVID-19 testing, and for engineers in particular, this is a unique opportunity to make a positive impact in the fight against COVID-19, by directly contributing in no small part to the national testing programme.”
Anyone interested in the Randox COVID-19 Engineering Drive should apply at careers.randox.com
Want to know more?
Contact us or visit our Randox Careers
Find out more about Randox Careers
Careers News
Vacancies
Our People
Careers Website
Health Secretary Matt Hancock publicly thanks Randox for āstepping up to the markā
Health Secretary Matt Hancock publicly thanks Randox for ‘stepping up to the mark’
On 23 April 2020, UK Health Secretary Matt Hancock personally thanked staff at Randox for the work we have done and continue to do, during the daily coronavirus briefing from Downing Street.
He said;
“I want to take this moment to applaud the private companies who have been involved…Boots, Amazon, Thermo Fisher, Randox, Rosch, Oxford Nanopore, GSK and Astrazeneca. They have really stepped up to the mark and I am grateful for each and every one.”
It is Randox’s priority to ensure that we contribute to the global effort to fight COVID-19, by testing at scale. We are therefore absolutely committed to the government testing scheme, which is focusing on key workers and the maintenance of critical national infrastructure – including that of the NHS.
In order to meet the requirements of this scheme, we have undertaken considerable reorganisation within the company by redeploying personnel – often to newly formed departments and newly formed teams. Everyone at Randox has a critical role to play in the practical application of COVID-19 testing and we appreciate all the hard work, patience, and flexibility of our staff.
Our work has greatly expanded the capacity for testing in the UK and we will continue to ramp up our capabilities, to both save lives and promote a timely return to a more normal society.
What we are doing is making a real and positive difference.
For further information please email randoxpr@randox.com
To watch the full version of the Daily Coronavirus Briefing from 23rd April, please click here.
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our Randox Products and Services
REAGENTS
RX SERIES
ACUSERA
BIOCHIP
Randox unveils whole pathogen molecular controls for SARS-CoV-2 (COVID-19)
16 April 2020
Randox unveils whole pathogen molecular controls for SARS-CoV-2 (COVID-19)
Whole pathogen quality controls to support accurate coronavirus testing have been developed by scientists in the UK.
The molecular controls, available from global diagnostics company Randox Laboratories, are currently being used as part of a nationwide testing programme for frontline NHS workers.
Alongside its pioneering COVID-19 tests, performed on its proprietary Biochip, Randox is using these third-party quality controls to ensure accurate coronavirus test and system performance, and ultimately, guarantee laboratory quality assurance.
Lynsey Adams, Randox Quality Control Manager, explained;
“Accurate and reliable laboratory testing is an essential aspect of COVID-19 disease management and outbreak control.
“Designed specifically for laboratories currently managing COVID-19 testing, Randox SARS-CoV-2 controls help ensure the accuracy and reliability of molecular assays used in the testing of suspected coronavirus samples, and importantly, give clinicians absolute confidence in any COVID-19 diagnoses they may make.”
Available under the brand name Qnostics, the new SARS-CoV-2 controls are manufactured using whole pathogens. They therefore mimic the patient sample, providing the best sample matrix for laboratories.
Lynsey continued;
“The Randox Qnostics SARS-CoV-2 controls are clinically relevant for full-process validation. Liquid frozen for user convenience and ease of use, the development of the controls using whole pathogen material ensures clinical relevance from extraction to amplification and detection.”
The new coronavirus controls from Randox, which contain the entire SARS-CoV-2 genome, including the conserved regions recommended by CDC and WHO, are compatible for use with both commercial and in-house testing methods, and are quantified by digital PCR to ensure batch to batch reproducibility.
Lynsey added;
“We are proud to be able to support the high demand for coronavirus testing by delivering a full COVID-19 testing package – not only our COVID-19 tests on the Randox Biochip, but now also the corresponding molecular control material that will ensure the delivery of accurate, and reliable results.
“The World Health Organization (WHO) has been very clear about the importance of testing in the global efforts to contain and delay COVID-19 and we are pleased that our new controls comply with guidelines not only from the WHO but also from the Centres for Disease Control and Prevention.”
Randox Qnostics SARS-CoV-2 Controls are heat-inactivated to be non-infectious and are manufactured to ISO 13485 standards.
Key Features and Benefits of Randox SARS-CoV-2 Qnostics Controls:
- Whole pathogen controls – the controls contain the entire SARS-CoV-2 genome meaning they are compatible with the majority of commercial and in-house assays, and target the CDC and WHO consensus sequences
- Monitor the entire testing process – whole pathogen controls are the ideal clinically relevant material for full-process validation, from extraction to amplification and detection, to ensure ultimate quality assurance in laboratories.
- Non-infectious – the controls are heat-inactivated and gamma-irradiation enabling safe handling of material.
- Highly characterised – the controls are quantified by digital PCR to ensure batch to batch reproducibility.
- Clinically relevant – performance data is available to support the clinical relevance and the compatibility with molecular assays currently in use in clinical laboratories.
- High Quality – the controls are manufactured under ISO 13485 guidelines and are therefore suitable for a broad range of usage.
- Liquid for Ease-of-Use – the controls are conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.
- Negative controls available – delivering a complete testing package.
For more information visit www.randox.com/coronavirus-randox